Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience

Alicia Roldán Pérez; Juan Andrés Vázquez Paganini; M José Penalva Moreno; Eugenio Giménez Mesa; Alba Sara Vilches Moreno; Claudia Nuñez-Torrón Stock; Regina Herráez García

doi:10.1002/ccr3.6116

Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience

Clin Case Rep. 2022 Jul 25;10(7):e6116. doi: 10.1002/ccr3.6116. eCollection 2022 Jul.

Authors

Alicia Roldán Pérez¹, Juan Andrés Vázquez Paganini¹, M José Penalva Moreno¹, Eugenio Giménez Mesa¹, Alba Sara Vilches Moreno¹, Claudia Nuñez-Torrón Stock¹, Regina Herráez García¹

Affiliation

¹ Department of Hemotherapy and Haematology Hospital Universitario Infanta Sofia San Sebastián de los Reyes Spain.

Abstract

We report our experience with venetoclax/hypomethylating agents (Ven/HMA) in 8 AML patients not candidates for intensive CT or refractory/relapsed with limited treatment options. The response rate was 50%. Venetoclax was well-tolerated in 62.5% of the patients. Ven/HMA provides a benefit particularly when used in patients without prior HMA exposure.

Keywords: Venetoclax; acute myeloid; elderly; hypomethylating agents; leukemia.

Publication types

Case Reports